Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors

Statement of Need

Immune checkpoint inhibition (ICI) targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 pathway (PD-1/PD-L1) has dramatically improved the care of patients with many advanced malignancies.1 Although ICI targeting CTLA-4 and PD-1/PD-L1 shows a broad range of activity, there are cancer types that seem to be resistant to such therapy. Therefore, identifying biomarkers that predict response to therapy and the occurrence of immune-mediated adverse reactions is crucial to ensure optimal patient outcomes.2 Based on the ever-expanding knowledge about the mechanism of action of various cancer immunotherapy approaches, including ICI targeting CTLA-4 and PD-1/PD-L1, the use of combination therapies may be the next logical step to improve response rates, increase duration of responses, and potentially increase cure rates.1-3

Attendees of this Grand Rounds series will gain an appreciation of the current and emerging approaches to immune checkpoint blockade in selected types of solid tumors, as well as the current status and future prospects for development of robust prognostic and predictive biomarkers of response to immunotherapy.

References
1Ott PA, et al. J Immunother Cancer. 2017. 2Topalian SL. Nat Rev Cancer. 2016. 3Mahoney KM, et al. Nat Rev Drug Discov. 2015.

Agenda

5 mins Welcome and Introductions
50 mins Presentation
5 mins Conversation with the Expert/Q&A

Target Audience

Oncology specialists (physicians, nurses, pharmacists) and other members of the oncology care team.

Learning Objectives

At the conclusion of this knowledge-based activity, participants will be able to:

  • Differentiate the mechanism of action and safety and efficacy of current and emerging immune checkpoint inhibitors used in selected types of solid tumors.
  • Appraise the rationale and latest data for combined immune checkpoint blockade in selected types of solid tumors.
  • Evaluate signs and symptoms of the immune-mediated adverse reactions associated with immune checkpoint blockade and strategies members of the healthcare team can employ to anticipate and effectively manage them.
  • Assess utility of PD-L1 expression and other immune variables as prognostic and predictive biomarkers of response to immune checkpoint inhibitors used in selected types of solid tumors.